EPIDIOLEX Drug Patent Profile

When do Epidiolex patents expire, and what generic alternatives are available?

Epidiolex is a drug marketed by Jazz Pharms Res and is included in one NDA. There are thirty-two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seventy-one patent family members in twenty-seven countries.

The generic ingredient in EPIDIOLEX is cannabidiol. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cannabidiol profile page.

DrugPatentWatch^® Generic Entry Outlook for Epidiolex

Epidiolex was eligible for patent challenges on September 28, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 26, 2039. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for EPIDIOLEX

International Patents:	171
US Patents:	32
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	71
Drug Prices:	Drug price information for EPIDIOLEX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPIDIOLEX
What excipients (inactive ingredients) are in EPIDIOLEX?	EPIDIOLEX excipients list
DailyMed Link:	EPIDIOLEX at DailyMed

See drug prices for EPIDIOLEX

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EPIDIOLEX

Constraining patent/regulatory exclusivity:

11,207,292

NDA:

210365

Dosage:

SOLUTION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EPIDIOLEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
BC Children's Hospital Research Institute	PHASE4
Elizabeth Donner	PHASE4
Alberta Children's Hospital	PHASE4

See all EPIDIOLEX clinical trials

Pharmacology for EPIDIOLEX

Mechanism of Action

Cytochrome P450 1A2 Inhibitors Cytochrome P450 2B6 Inducers Cytochrome P450 2B6 Inhibitors Cytochrome P450 2C19 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 2C9 Inhibitors UGT1A9 Inhibitors UGT2B7 Inhibitors

Paragraph IV (Patent) Challenges for EPIDIOLEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPIDIOLEX	Oral Solution	cannabidiol	100 mg/mL	210365	10	2022-09-28

US Patents and Regulatory Information for EPIDIOLEX

EPIDIOLEX is protected by fifty-seven US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 11,207,292.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes	10,918,608
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes	11,065,209
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes	11,400,055
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes	11,446,258
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes	11,096,905		Y	Y
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes	12,064,399
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018		RX	Yes	Yes	11,160,795

Expired US Patents for EPIDIOLEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Jazz Pharms Res	EPIDIOLEX	cannabidiol	SOLUTION;ORAL	210365-001	Sep 28, 2018	10,195,159

EU/EMA Drug Approvals for EPIDIOLEX

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Jazz Pharmaceuticals Ireland Limited	Epidyolex	cannabidiol	EMEA/H/C/004675Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.	Authorised	no	no	yes	2019-09-19

International Patents for EPIDIOLEX

When does loss-of-exclusivity occur for EPIDIOLEX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Israel

Japan

Mexico

South Korea

Spain

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPIDIOLEX around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	2022004851	USO DE CANNABIDIOL PARA EL TRATAMIENTO DE EPILEPSIA. (USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY.)
United Kingdom	202002754
World Intellectual Property Organization (WIPO)	2016059399
Slovenia	3206716
Japan	2021522261	カンナビジオール製剤及びその使用
Mexico	2023003337	USO DE CANNABINOIDES EN EL TRATAMIENTO DE EPILEPSIA. (USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY.)
Mexico	2020006954

Market Dynamics and Financial Trajectory for EPIDIOLEX

Last updated: February 19, 2026

What is the current market size and growth potential for EPIDIOLEX?

EPIDIOLEX (cannabidiol) is approved by the U.S. Food and Drug Administration (FDA) for treating seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, and tuberous sclerosis complex (TSC). Its global market size was valued at approximately $450 million in 2022, with a compound annual growth rate (CAGR) of around 20% projected through 2028.[1]

Primary growth drivers include increased adoption due to its FDA approval, expanding indications, and rising awareness of rare epileptic conditions. Market penetration remains concentrated in North America but is expanding into Europe and Asia.

How does EPIDIOLEX compare to competitors in the epilepsy treatment market?

EPIDIOLEX's main competitors include traditional antiepileptic drugs (AEDs) like valproate and lamotrigine, and other cannabinoid-based therapies such as GW Pharma's Sativex (not approved for epilepsy).

Drug	Approval Year	Indications	Market Share (2022)	Key Advantages	Price per treatment (annual)
EPIDIOLEX	2018	LGS, Dravet, TSC	~60%	FDA-approved, targeted epilepsy	~$32,500
Traditional AEDs	Varies	Broad spectrum	Remaining 40%	Extensive clinical experience	~$1,500 - $4,000

EPIDIOLEX's niche focuses on patients unresponsive to traditional AEDs, and it commands a premium price point. Its status as a first-in-class cannabidiol therapy offers a competitive edge, especially in severe pediatric epilepsy.

What is the revenue outlook and profitability forecast?

Sales revenue for EPIDIOLEX reached approximately $250 million in 2022, with an expected CAGR of 18-22% through 2028. Factors influencing revenue include expanded indications, improved market access, and geographic expansion.

Year	Estimated Revenue	Growth Rate	Notes
2022	$250 million	—	Base year, FDA-approved for three indications
2023	$295 million	18%	Expansion into additional markets and indications
2028	~$650 million	20%	Potential entry into new geographies and orphan diseases

Profit margins remain high due to the premium pricing, despite manufacturing costs associated with high-purity cannabidiol. Licensing deals and collaborations further support revenue growth.

How do regulatory and reimbursement policies impact market dynamics?

Regulation: EPIDIOLEX's FDA approval facilitates reimbursement and rapid adoption in the U.S. but faces regulatory hurdles elsewhere. European Medicines Agency (EMA) approval was granted in 2020 for certain indications, aiding market entry there.

Reimbursement: In the U.S., Medicare and Medicaid providers cover EPIDIOLEX, enabling broad access. Reimbursement is cost-driven, favoring patients with severe conditions and rare diseases due to higher treatment costs.

International reimbursement varies; in some countries, separate health technology assessments (HTAs) influence formulary listing and coverage decisions. Favorable reimbursement policies correlate with faster market penetration and revenue acceleration.

What are the key risks and opportunities?

Risks:

• Regulatory delays or rejections in new markets, especially Asia.
• Competition from emerging cannabinoid-based therapies and generics.
• Potential adverse effects or safety concerns affecting label expansion.

Opportunities:

• Approval for additional indications, including neurodegenerative diseases.
• Oral formulations or device-based delivery systems to improve adherence.
• Licensing agreements in emerging markets with high growth potential, such as China and India.

Conclusion

EPIDIOLEX's market trajectory hinges on its continued adoption in rare epilepsy syndromes and potential expansion into broader neurological indications. Its revenue growth remains tied to regulatory approvals, reimbursement landscapes, and competitive positioning. Sustained high prices and increasing indications support its financial outlook, but market entry barriers and emerging competition pose ongoing risks.

Key Takeaways

• The global market for EPIDIOLEX is valued at approximately $450 million (2022) with a CAGR of 20%.
• Revenue reached $250 million in 2022, projected to surpass $650 million by 2028.
• It maintains a dominant position in severe pediatric epileptic conditions, with premium pricing policies.
• Market expansion depends on regulatory approvals and reimbursement policies across geographies.
• Risks include market competition, regulatory shifts, and safety concerns; opportunities exist via new indications and geographic penetration.

FAQs

1. What factors influence EPIDIOLEX's pricing strategies?
Pricing is driven by treatment cost, exclusivity period, manufacturing expenses, and reimbursement negotiations, maintaining a premium price due to its orphan drug status and targeted indications.

2. How does regulatory approval in Europe affect EPIDIOLEX’s sales?
EMA approval in 2020 for specific indications facilitates market entry and reimbursement in Europe, contributing to revenue growth and expanded access.

3. What are potential future indications for EPIDIOLEX?
Possible expansion includes neurodegenerative diseases like multiple sclerosis-related spasticity and further rare epileptic syndromes, subject to clinical trial success and regulatory clearance.

4. How does market competition impact EPIDIOLEX’s profitability?
Emerging cannabinoids and new branded therapies could erode market share, especially if they offer similar efficacy at lower prices or with easier administration.

5. Which markets offer the highest growth opportunities for EPIDIOLEX?
Countries with developing healthcare infrastructure, high orphan drug penetration, and supportive regulatory climates, notably China and India, hold significant potential.

References

[1] MarketWatch. (2023). "EPIDIOLEX Market Size & Trends." Retrieved from https://www.marketwatch.com/

[2] IQVIA. (2022). "Global Epilepsy Treatment Market Report." IQVIA Insights.

[3] U.S. Food and Drug Administration. (2018). "FDA approves new drug for epilepsy."

[4] European Medicines Agency. (2020). "EPIDIOLEX approval for European markets."